June 26, 2023 07:42 AM EDTUpdated 11:01 AM
R&D
Pharma

Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Kyle LaHucik

Senior Reporter

Pfiz­er chief Mikael Dol­sten told an­a­lysts last month that the Big Phar­ma would “cher­ry-pick the win­ner” be­tween its two mid-stage oral GLP-1s. The drug­mak­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times